Disruption Opinion Technology

035: #ProcureTech 2016 Wrap Up: Is Technology Disrupting the Procurement Delivery Model?, with Jason Busch

Last week I joined almost 300 procurement peers from around the world at the first Spend Matters ISM Global Procurement Tech Summit in Baltimore, Maryland. As the event came to a close, I spent 15 minutes catching up with Jason Busch – Founder and Head of Strategy at Azul Partners and Spend Matters – discussing what it took to put together an event of this size, and the key takeaways that Jason took from from the conference.

iTunesSubscribe | Rate & Review

*note: due to Easter Week, this week’s episode with Jason replaces the regular Friday Show this week*

In this episode, you will learn:

  • Jason’s motivation for hosting the conference, and how his team determined the theme and content that the conference covered.
  • The changes in procurement technology that are taking place that will impact how we buy in the future
  • The limitations of end to end procurement technology suites
  • Are we moving towards a future of platforms and apps?
  • What is the potential of cognitive learning technologies?
  • Will ProcureTech be back in 2017?

Links and Resources:

Thanks for Listening!

 

About the author

Philip Ideson

Philip Ideson is passionate about the role that procurement professionals and leaders can plan in creating competitive advantage for their organizations in ways that go beyond the traditional value proposition.

Philip founded Art of Procurement as a way for the procurement community to learn from each other, increasing the impact they have on their organizations. In 2017, he co-founded Palambridge, a virtual platform of procurement experts, technology, and intelligence. Palambridge provides a broad range of flexible procurement solutions, available on-demand.

Prior to Art of Procurement and Palambridge, Philip enjoyed a career that spanned the procurement value chain, working across three continents for organizations such as Accenture, Procurian, Ally Financial, Pfizer and Ford Motor Company.

Leave a Comment